NYSE
17.48USD
-0.07 (-0.40%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
55.6B
P/E
—
EPS
—
Beta
0.09
52W range
12.99-18.9
Day range
17.38–17.64
Open
17.38
Prev close
17.55
Volume
2.2M
Avg volume
3.3M
Dividend
0.63
IPO
2010-01-05
https://seekingalpha.com/article/4935261-protagonist-therapeutics-strong-buy-icotyde-fda-approval-and-pn-881-advancement · 8/12/2026+0.30
https://www.fool.com/coverage/better-buy/2026/07/04/dyne-therapeutics-vs-recursion-pharmaceuticals-which-development-stage-pharma-stock-is-a-better-buy-in-2026/ · 7/4/2026+0.20
https://www.prnewswire.com/news-releases/2026-asco--innovent-presents-long-term-follow-up-results-from-the-poc-study-of-ibi363-tak-928-pd-1il-2-bias-bispecific-fusion-protein-showing-robust-survival-benefits-in-advanced-immunotherapy-resistant-non-small-cell-lung-302786450.html · 6/1/2026+0.80
https://www.prnewswire.com/news-releases/2026-asco--innovent-presents-preliminary-poc-data-of-ibi363-tak-928-pd-1il-2-bias-bispecific-fusion-protein-in-first-line-advanced-nsclc-302786452.html · 6/1/2026
https://www.globenewswire.com/news-release/2026/05/31/3303964/0/en/Ascentage-Pharma-Presents-Data-on-Olverembatinib-in-CML-LBP-and-Ph-BCP-ALL-at-ASCO-2026.html · 5/31/2026+0.20
https://www.globenewswire.com/news-release/2026/05/31/3303966/0/en/Ascentage-Pharma-Presents-Updated-Clinical-Data-for-Olverembatinib-as-Second-Line-Therapy-in-CML-CP-at-ASCO-2026.html · 5/31/2026+0.20
https://www.prnewswire.com/news-releases/halozyme-reports-first-quarter-2026-results-and-reiterates-2026-financial-guidance-302768578.html · 5/11/2026+0.50
https://www.prnewswire.com/news-releases/innovent-announces-ibi363-pd-1il-2-bias-bispecific-fusion-protein-received-third-nmpa-breakthrough-therapy-designation-for-msspmmr-metastatic-colorectal-cancer-302767628.html · 5/11/2026+0.40
https://www.zacks.com/stock/news/2903495/kros-2026-watchlist-3-catalysts-that-could-reset-sentiment · 4/20/2026+0.20
https://www.zacks.com/stock/news/2898234/is-adma-poised-for-margin-growth-and-supply-expansion-in-2026 · 4/10/2026+0.00
https://www.globenewswire.com/news-release/2026/04/03/3268105/0/en/Denali-Therapeutics-Regains-Full-Rights-to-Investigational-Therapy-DNL593-PTV-PGRN-for-GRN-related-Frontotemporal-Dementia-FTD-GRN.html · 4/3/2026+0.00
https://www.cnbc.com/2026/03/31/eli-lilly-to-acquire-centessa-and-sleep-disorder-drugs.html · 3/31/2026-0.20
Takeda Pharmaceutical Company Limited is a prominent global biopharmaceutical entity dedicated to the discovery, development, manufacturing, commercialization, and out-licensing of pharmaceutical products. The company's operations extend across a vast international footprint, encompassing Japan, the United States, Europe, Canada, Latin America, Russia, and numerous other Asian and worldwide markets. Its extensive portfolio of medicines targets critical therapeutic areas, including digestive disorders (gastroenterology), rare diseases, plasma-derived treatments, cancer care (oncology), and neurological conditions. Takeda markets these products under various well-recognized brand names, such as Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig. To further its innovative endeavors, Takeda engages in a wide array of strategic partnerships. These include out-licensing arrangements, notably with Neurocrine Biosciences, Inc.; numerous collaboration and in-licensing agreements with institutions like the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., Ovid Therapeutics Inc., and Evox Therapeutics Ltd.; and a licensing deal with ProThera Biologics Inc. The company also fosters research collaborations and licensing agreements with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio. Furthermore, it maintains strategic alliances with Egle Therapeutics SAS, Evotec SE, Neurocrine Biosciences, Inc., Carmine Therapeutics, KSQ Therapeutics, and Anima Biotech. Founded in 1781, Takeda Pharmaceutical Company Limited is headquartered in Tokyo, Japan.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works